Showing results (51-60 of 80) with videos related to
Sort By:
Pageof 8
Journal of Immunological Methods|October 27, 2019
Comments on EuroFlow standard operating procedures for instrument setup and compensation for BD FACS Canto II, Navios and BD FACS Lyric instrumentsHana Glier, Michaela Novakova, Jeroen Te Marvelde, et al.Blood|March 25, 2020
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclaxEugen Tausch, Christof Schneider, Sandra Robrecht, et al.The New England Journal of Medicine|January 10, 2014
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsValentin Goede, Kirsten Fischer, Raymonde Busch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.Blood|April 15, 2024
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trialMoritz Fürstenau, Adam Giza, Jonathan Weiss, et al.Nature Medicine|December 9, 2023
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trialOthman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht, et al.Cytometry. Part B, Clinical Cytometry|August 15, 2006
Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization processRemi Letestu, Andy Rawstron, Paolo Ghia, et al.The Lancet. Haematology|September 17, 2017
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 studyAnna Maria Fink, Jasmin Bahlo, Sandra Robrecht, et al.Blood|March 25, 2025
NGS-based IG/TR rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturationMichaela Kotrova, Constantin Proske, Nikos Darzentas, et al.Haematologica|February 29, 2020
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trialPaula Cramer, Julia V Tresckow, Sandra Robrecht, et al.Pageof 8